"We were hopeful to get a larger market share this year," Novavax CEO John Jacobs said in an interview, adding the company ...

Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call Transcript ... Joining me today is John Jacobs, our President and CEO, who ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

On Tuesday, Novavax Inc (NASDAQ:NVAX) reported third-quarter 2024 sales of $84.5 million, compared to $186.99 million a year, ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

The CEO of Hungarian pharmaceutical company Richter reiterated 2024 guidance on Tuesday after it reported higher ...

The vaccine maker posted a narrower third-quarter loss than expected at 76 cents a share. Revenue was $85 million, compared ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

led by CEO John Jacobs, declined to comment beyond its filings with the Securities and Exchange Commission and press release. Successfully completing this late-stage trial is vital to Novavax’s ...